Kreuth III

European consensus proposals for treatment of haemophilia with coagulation factor concentrates

P. Giangrande, R. Seitz, M. E. Behr-Gross, K. Berger, A. Hilger, H. Klein, W. Schramm, P. M. Mannucci

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

This report summarizes recommendations relating to haemophilia therapy arising from discussions among experts from 36 European countries during the Kreuth III meeting in April 2013. To optimize the organization of haemophilia care nationally, it is recommended that a formal body be established in each country to include the relevant clinicians, national haemophilia patient organization, health ministry, paying authority and (if appropriate) regulatory authorities. The minimum factor VIII consumption level in a country should be 3 I.U. per capita. Decisions on whether to adopt a new product should not be based solely on cost. Prophylaxis for children with severe haemophilia is already recognized as the optimum therapy. Ongoing prophylaxis for individual adults should also be provided when required based on clinical decision making by the clinician in consultation with the patient. Children with inhibitors who have failed, or who are not suitable for, immune tolerance therapy should be offered prophylaxis with bypassing agents. Single factor concentrates should be used as therapy wherever possible in patients with rare bleeding disorders. Orphan drug designation for a factor concentrate should not be used to hinder the development, licencing and marketing of other products for the same condition which have demonstrably different protein modification or enhancement.

Original languageEnglish
Pages (from-to)322-325
Number of pages4
JournalHaemophilia
Volume20
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Blood Coagulation Factors
Hemophilia A
Orphan Drug Production
Organizations
Immune Tolerance
Factor VIII
Licensure
Therapeutics
Marketing
Referral and Consultation
Hemorrhage
Costs and Cost Analysis
Health
Proteins

Keywords

  • Factor VIII
  • Guidelines
  • Haemophilia
  • Prophylaxis
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Genetics(clinical)
  • Medicine(all)

Cite this

Kreuth III : European consensus proposals for treatment of haemophilia with coagulation factor concentrates. / Giangrande, P.; Seitz, R.; Behr-Gross, M. E.; Berger, K.; Hilger, A.; Klein, H.; Schramm, W.; Mannucci, P. M.

In: Haemophilia, Vol. 20, No. 3, 2014, p. 322-325.

Research output: Contribution to journalArticle

Giangrande, P, Seitz, R, Behr-Gross, ME, Berger, K, Hilger, A, Klein, H, Schramm, W & Mannucci, PM 2014, 'Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates', Haemophilia, vol. 20, no. 3, pp. 322-325. https://doi.org/10.1111/hae.12440
Giangrande, P. ; Seitz, R. ; Behr-Gross, M. E. ; Berger, K. ; Hilger, A. ; Klein, H. ; Schramm, W. ; Mannucci, P. M. / Kreuth III : European consensus proposals for treatment of haemophilia with coagulation factor concentrates. In: Haemophilia. 2014 ; Vol. 20, No. 3. pp. 322-325.
@article{2ce971b95f6a404b9f75fcc71ac690da,
title = "Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates",
abstract = "This report summarizes recommendations relating to haemophilia therapy arising from discussions among experts from 36 European countries during the Kreuth III meeting in April 2013. To optimize the organization of haemophilia care nationally, it is recommended that a formal body be established in each country to include the relevant clinicians, national haemophilia patient organization, health ministry, paying authority and (if appropriate) regulatory authorities. The minimum factor VIII consumption level in a country should be 3 I.U. per capita. Decisions on whether to adopt a new product should not be based solely on cost. Prophylaxis for children with severe haemophilia is already recognized as the optimum therapy. Ongoing prophylaxis for individual adults should also be provided when required based on clinical decision making by the clinician in consultation with the patient. Children with inhibitors who have failed, or who are not suitable for, immune tolerance therapy should be offered prophylaxis with bypassing agents. Single factor concentrates should be used as therapy wherever possible in patients with rare bleeding disorders. Orphan drug designation for a factor concentrate should not be used to hinder the development, licencing and marketing of other products for the same condition which have demonstrably different protein modification or enhancement.",
keywords = "Factor VIII, Guidelines, Haemophilia, Prophylaxis, Treatment",
author = "P. Giangrande and R. Seitz and Behr-Gross, {M. E.} and K. Berger and A. Hilger and H. Klein and W. Schramm and Mannucci, {P. M.}",
year = "2014",
doi = "10.1111/hae.12440",
language = "English",
volume = "20",
pages = "322--325",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "3",

}

TY - JOUR

T1 - Kreuth III

T2 - European consensus proposals for treatment of haemophilia with coagulation factor concentrates

AU - Giangrande, P.

AU - Seitz, R.

AU - Behr-Gross, M. E.

AU - Berger, K.

AU - Hilger, A.

AU - Klein, H.

AU - Schramm, W.

AU - Mannucci, P. M.

PY - 2014

Y1 - 2014

N2 - This report summarizes recommendations relating to haemophilia therapy arising from discussions among experts from 36 European countries during the Kreuth III meeting in April 2013. To optimize the organization of haemophilia care nationally, it is recommended that a formal body be established in each country to include the relevant clinicians, national haemophilia patient organization, health ministry, paying authority and (if appropriate) regulatory authorities. The minimum factor VIII consumption level in a country should be 3 I.U. per capita. Decisions on whether to adopt a new product should not be based solely on cost. Prophylaxis for children with severe haemophilia is already recognized as the optimum therapy. Ongoing prophylaxis for individual adults should also be provided when required based on clinical decision making by the clinician in consultation with the patient. Children with inhibitors who have failed, or who are not suitable for, immune tolerance therapy should be offered prophylaxis with bypassing agents. Single factor concentrates should be used as therapy wherever possible in patients with rare bleeding disorders. Orphan drug designation for a factor concentrate should not be used to hinder the development, licencing and marketing of other products for the same condition which have demonstrably different protein modification or enhancement.

AB - This report summarizes recommendations relating to haemophilia therapy arising from discussions among experts from 36 European countries during the Kreuth III meeting in April 2013. To optimize the organization of haemophilia care nationally, it is recommended that a formal body be established in each country to include the relevant clinicians, national haemophilia patient organization, health ministry, paying authority and (if appropriate) regulatory authorities. The minimum factor VIII consumption level in a country should be 3 I.U. per capita. Decisions on whether to adopt a new product should not be based solely on cost. Prophylaxis for children with severe haemophilia is already recognized as the optimum therapy. Ongoing prophylaxis for individual adults should also be provided when required based on clinical decision making by the clinician in consultation with the patient. Children with inhibitors who have failed, or who are not suitable for, immune tolerance therapy should be offered prophylaxis with bypassing agents. Single factor concentrates should be used as therapy wherever possible in patients with rare bleeding disorders. Orphan drug designation for a factor concentrate should not be used to hinder the development, licencing and marketing of other products for the same condition which have demonstrably different protein modification or enhancement.

KW - Factor VIII

KW - Guidelines

KW - Haemophilia

KW - Prophylaxis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84898614378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898614378&partnerID=8YFLogxK

U2 - 10.1111/hae.12440

DO - 10.1111/hae.12440

M3 - Article

VL - 20

SP - 322

EP - 325

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 3

ER -